FDA expert committee votes in favor of Replimune's melanoma treatment

An FDA expert committee voted on July 30 in favor of Replimune’s experimental melanoma treatment, RP1, according to a live-blogged proceeding reported by STAT News. The panel’s endorsement concerns an oncolytic virus therapy, a treatment approach that uses modified viruses to attack cancer cells, developed for patients with melanoma, a form of skin cancer.

STAT News covered the FDA meeting in real time, tracking the committee’s deliberations and eventual vote. The outlet’s reporting frames the vote as a step in the regulatory review process for RP1, moving the drug closer to a potential approval decision by the FDA. STAT did not report a final agency decision as part of this coverage, only the committee’s recommendation.

Expert committee votes of this kind inform, but do not bind, the FDA’s ultimate ruling on whether to approve a new treatment. The agency typically weighs the panel’s assessment alongside its own review of clinical trial data before issuing a decision.

Melanoma remains one of the more aggressive forms of skin cancer, and new treatment approaches are closely watched by oncologists and patients. STAT News’ live coverage tracked the committee’s questions and discussion leading up to the vote, though further detail on the trial data underlying the committee’s decision was not included in the material reviewed here.